Clinical trial

A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma

NCT00140049

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-07-01

PhasePHASE4

Study timeline

Study start (unknown)2005-07-01Date precision: month

Registry last updated2021-02-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Glaucoma, Open Angleunresolved

Ocular Hypertensionunresolved

Interventions

XalacomDRUG

CosoptDRUG · verified · RxNorm: Cosopt

Sponsors & collaborators

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.lead sponsor

Mapped research locations

MilanItaly1 MarseilleFrance1 LyonFrance1 CaenFrance1 Clermont-FerrandFrance1 Saint-HerblainFrance1 GenovaItaly1 PisaItaly1 MalmöSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00140049 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.